MONOCLONAL AND POLYCLONAL MEGAKARYOCYTE-CSF ANTIBODIES

从骨髓中的祖细胞产生巨核细胞可以是 巨核细胞集落刺激因子 因子（Meg-CSF）。 巨核细胞的谱系特异性刺激 Meg-CSF和随后的血小板数量增加具有很大的临床意义。 在治疗由抗癌或 抗艾滋病毒疗法。 多克隆和单克隆抗体的生产 本I期SBIR提出的Meg-CSF将有助于纯化 通过亲和层析法对Meg-CSF进行纯化，并鉴定 表达Meg-CSF cDNA的重组克隆。 此外，这种抗体 将使得能够开发分析，例如酶联免疫分析， 免疫吸附试验（ELISA），以确定血清或尿液中的Meg-CSF水平， 正在接受化疗或患有血小板减少症的患者 其他原因。 免疫家兔获得多克隆抗体 并且提出了小鼠的体外和体内免疫， 单克隆抗体生产。

The production of megakaryocytes from progenitor cells in the marrow can be stimulated by a lineage-specific factor - megakaryocyte colony-stimulating factor (Meg-CSF). The lineage-specific stimulation of megakaryocytes by Meg-CSF and subsequent increase in platelet number has great clinical significance in treating thrombocytopenia resulting from anti-cancer or anti-HIV therapies. The production of polyclonal and monoclonal antibodies to Meg-CSF proposed by this Phase I SBIR would facilitate the purification of Meg-CSF by affinity chromatography, and the identification of recombinant clones expressing Meg-CSF cDNA. In addition, such antibodies will enable the development of assays, such as an enzyme-linked immunosorbent assay (ELISA), to determine serum or urine Meg-CSF levels in those patients undergoing chemotherapy or who have thrombocytopenia from other causes. Rabbits will be immunized to obtain polyclonal antibodies and both in vitro and in vivo immunization of mice is proposed for monoclonal antibody production.